ArcticZymes Technologies ASA

LSE:0DRV Stock Report

Market Cap: NOK 710.9m

ArcticZymes Technologies Valuation

Is 0DRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0DRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0DRV (NOK14.12) is trading below our estimate of fair value (NOK37.77)

Significantly Below Fair Value: 0DRV is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0DRV?

Other financial metrics that can be useful for relative valuation.

0DRV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA636.1x
PEG Ratio2.1x

Price to Sales Ratio vs Peers

How does 0DRV's PS Ratio compare to its peers?

The above table shows the PS ratio for 0DRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
TRX Tissue Regenix Group
1.8x15.1%UK£44.2m
PBX ProBiotix Health
5xn/aUK£10.7m
BVXP Bioventix
15.2xn/aUK£206.2m
VRCI Verici Dx
2.4x78.8%UK£8.2m
0DRV ArcticZymes Technologies
6.4x14.1%NOK 710.9m

Price-To-Sales vs Peers: 0DRV is expensive based on its Price-To-Sales Ratio (6.4x) compared to the peer average (6.1x).


Price to Earnings Ratio vs Industry

How does 0DRV's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 0DRV is good value based on its Price-To-Sales Ratio (6.4x) compared to the European Biotechs industry average (8.5x).


Price to Sales Ratio vs Fair Ratio

What is 0DRV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0DRV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0DRV's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0DRV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 14.12
NOK 16.00
+13.3%
6.3%NOK 17.00NOK 15.00n/a2
Oct ’25NOK 17.00
NOK 24.50
+44.1%
6.1%NOK 26.00NOK 23.00n/a2
Sep ’25NOK 18.98
NOK 24.50
+29.1%
6.1%NOK 26.00NOK 23.00n/a2
Aug ’25NOK 25.70
NOK 27.50
+7.0%
9.1%NOK 30.00NOK 25.00n/a2
Jul ’25NOK 25.85
NOK 27.50
+6.4%
9.1%NOK 30.00NOK 25.00n/a2
Jun ’25NOK 24.50
NOK 27.50
+12.2%
9.1%NOK 30.00NOK 25.00n/a2

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies